|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02196 FOSUN PHARMA
Nominal 
15.160 -0.200 (-1.302%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Turnover | 20,383,158 | -4.376% | 21,315,899 | 21,282,131 | 16,877,537 | 13,965,179 |
| Cost of Sales | (10,463,386) | -2.198% | (10,698,520) | (11,578,145) | (8,256,422) | (6,215,872) |
| Gross Profit | 9,919,772 | -6.570% | 10,617,379 | 9,703,986 | 8,621,115 | 7,749,307 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (38,038) | -34.390% | (57,976) | (22,860) | (14,804) | (42,765) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 841,320 | -17.700% | 1,022,263 | 799,019 | 831,809 | 652,406 | |
| Profit / (Loss) before Taxation | 1,931,201 | -27.443% | 2,661,640 | 2,358,480 | 3,304,229 | 2,301,688 | |
| Taxation | (381,469) | -37.489% | (610,245) | (509,086) | (550,647) | (392,081) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (324,933) | 21.356% | (267,753) | (307,509) | (271,209) | (194,897) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,224,799 | -31.332% | 1,783,642 | 1,541,885 | 2,482,373 | 1,714,710 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Net Finance Costs / (Income) | 520,576 | 20.537% | 431,881 | 320,482 | 304,120 | 331,442 |
| Depreciation & Amortisation | 1,546,990 | -1.151% | 1,565,006 | 1,064,356 | 945,447 | 836,268 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| EPS (cts) | 46.000 | -31.343% | 67.000 | 60.000 | 97.000 | 67.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 17.561 | -- | 16.996 | -- | 14.751 | 12.869 |
| Remarks: | Real time quote last updated: 06/11/2024 11:16 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,224,799 |
| %Change | -31.332% |
| EPS / (LPS) | RMB 0.460 |
| NBV Per Share (¥) | RMB 17.561 |